Stocks › Biotechnology › SLN

Silence Therapeutics SLN

US equityMarket cap rank #3610Biotechnology

$9.82 −$0.01 (-0.10%)

Pre-market · Oct 8, 8:20 am ET · After hours $9.82 0.00%

Open$9.77

Prev close$9.83

Day range$9.60 – $10.14

Volume1.32M

Market cap$610.35M

P/E (TTM)–

Dividend yield–

Earnings

Average move on report day±1.3%last 7 reports

Closed higher0 of 70% of the time

Best reaction+0.0%

Worst reaction-5.2%

Stock move on the day after each report

Quarter	Report date	Timing	Implied move	Actual move	Versus implied
2024/Q4	27 Feb 2025	Pre Market	±21.6%	-1.05%	Within range
2023/Q4	13 Mar 2024	Pre Market	–	-1.12%	–
2022/Q4	15 Mar 2023	None	–	-5.18%	–
2021/Q4	17 Mar 2022	None	–	-1.71%	–
2021/Q2	12 Aug 2021	None	–	+0.00%	–
2020/Q4	30 Mar 2021	None	–	+0.00%	–
2020/Q2	14 Sep 2020	None	–	+0.00%	–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00-100.0% YoY

Operating profit-$13.87M+38.8% YoY

Net profit-$12.27M+55.2% YoY

Diluted EPS-$0.27+52.6% YoY

Free cash flow$1.52M+107.0% YoY

Operating cash flow$1.52M

Revenue, last 8 quarters

Net profit, last 8 quarters

Profitability & balance sheet

Gross margin85.9%

Operating margin-11,106.8%

Net margin-9,748.5%

Return on equity-90.4%

Return on assets-44.1%

Return on invested capital-90.3%

Current ratio7.42

Liabilities / assets63.8%

Cash & investments$72.05M

Total debt$9,000.00

Net cash (debt)$72.05M

Discussion

No comments yet — be the first to weigh in on SLN.